OP-101

DRUG3 trials

Sponsors

Orpheris, Inc., Ashvattha Therapeutics, Inc.

Conditions

COVID-19Healthy

Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

CompletedNCT03500627

Orpheris, Inc.Healthy

Start: 2018-03-30End: 2018-07-20Updated: 2018-09-17

A Clinical Study to Measure the Effect of OP-101 After Being Administered Subcutaneous in Healthy Volunteers

CompletedNCT04321980

Orpheris, Inc.Healthy

Start: 2020-03-19End: 2020-05-22Updated: 2021-06-14

Phase 2

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

TerminatedNCT04458298

Ashvattha Therapeutics, Inc.COVID-19

Start: 2020-08-11End: 2022-08-12Updated: 2023-02-13